Last reviewed · How we verify
NCT04948437
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
trial in Thyroid Cancer in 103 participants. Participants enrolled and being followed up; not accepting new ones.
8 April 2026
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 103 |
| Start date | 19 August 2021 |
| Primary completion | 8 April 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across Taiwan |
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
- Papillary Thyroid Cancer — all drugs for Papillary Thyroid Cancer →
- Follicular Thyroid Cancer — all drugs for Follicular Thyroid Cancer →
Sponsor
National Taiwan University Hospital
Who can join
Adults 20 to 80, any sex, with Thyroid Cancer or Papillary Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years. The investigators' study already enrolled seventy-three patients with thyroid cancer, and the investigators plan to enroll 30 new patients in this consecutive research study. All patients received total thyroidectomy under clinically surgical judgement in initial therapeutic option. The investigators also further found some difference between papillary thyroid cancer and follicular thyroid cancer, and the investigators will continue annually to closely monitor the change of U-Ex Tg and urinary exosomal galectin-3 between differently cellular types of thyroid cancers.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression.
Lopez K, Lai SWT, Lopez Gonzalez EJ, Dávila RG, et al · · 2023 · cited 49× · PMID 37025182 · DOI 10.3389/fcell.2023.1154576 -
Exosomes: Insights and therapeutic applications in cancer.
Panigrahi AR, Srinivas L, Panda J. · · 2022 · cited 27× · PMID 35551002 · DOI 10.1016/j.tranon.2022.101439 -
The biological function of tumor-derived extracellular vesicles on metabolism.
Fu X, Song J, Yan W, Downs BM, et al · · 2023 · cited 22× · PMID 37349803 · DOI 10.1186/s12964-023-01111-6 -
Exosomes and solid cancer therapy: where are we now?
Zemanek T, Danisovic L, Nicodemou A. · · 2025 · cited 15× · PMID 39961904 · DOI 10.1007/s12032-025-02626-3 -
Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma.
Jiang Z, Zhang W, Sha G, Wang D, et al · · 2022 · cited 11× · PMID 36428567 · DOI 10.3390/cancers14225475 -
Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
Shi Y, Tang D, Li X, Xie X, et al · · 2022 · cited 10× · PMID 35677161 · DOI 10.3389/fonc.2022.889034 -
Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research.
Li Z, Yan J, Li X, Chen H, et al · · 2025 · cited 7× · PMID 40046812 · DOI 10.3389/fbioe.2025.1487627 -
Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage.
Schiano C, Balbi C, de Nigris F, Napoli C. · · 2023 · cited 7× · PMID 37108672 · DOI 10.3390/ijms24087509
Verify or expand the search:
- PubMed search for NCT04948437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04948437 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04948437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing